Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Outcomes following SARS-CoV-2 infection among individuals living with and without HIV; a Danish nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. High incidence of subclinical peripheral artery disease in people with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Risk of subarachnoid haemorrhages and aneurysms in Danish people with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dentist's visits and risk of brain abscess: a nationwide, population-based case control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To compare the risk of a positive SARS-CoV-2 test and COVID-19 outcomes in people living with HIV (PLWH) with the general population, and estimate the association with vaccination status.

DESIGN: A nationwide, population based, matched cohort study.

METHODS: We included all Danish PLWH ≥18 years (n = 5,276) and an age-and sex matched general population cohort (n = 42,308).We used Cox regression analyses to calculate (adjusted) incidence rate ratios [(a)IRR] and further stratified and restricted the analyses.

RESULTS: We observed no major difference in risk of first positive SARS-CoV-2 test [aIRR: 0.8 (95%CI: 0.8-0.9)], but a higher risk of first hospital contact with COVID-19 and hospitalization with severe COVID-19 for PLWH vs. controls [IRR: 2.0; (1.6-2.5), 1.8 (1.4-2.3)]. Risk of first hospitalization decreased substantially in PLWH with calendar time [First half of year 2022 vs. 2020 IRR: 0.3; (0.2-0.6)], whereas the risk compared to population controls remained almost 2-fold increased. We did not observe increased risk of death after SARS-CoV-2 infection [aIRR: 0.7 (95%CI: 0.3-2.0)]. Compared to PLWH who had received two vaccines PLWH who receiving a third vaccine had reduced risk of first positive SARS-CoV-2 test, death (individuals ≥60years) and hospitalization [aIRR: 0.9 (0.7-1.0); 0.2 (0.1-0.7); 0.6 (0.2-1.2)].

CONCLUSION: PLWH have almost the same risk of a positive SARS-CoV-2 test as the general population. Although risk of hospital contacts and severe outcomes following SARS-CoV-2 infection is increased, the risk of death does not seem to be substantially increased. Importantly, a third vaccine is associated with reduced risk of infection, and death.

OriginalsprogEngelsk
TidsskriftAIDS
ISSN0269-9370
DOI
StatusE-pub ahead of print - 20 sep. 2022

Bibliografisk note

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

ID: 84663065